Sign In Join Help
 
Changchun Changsheng Life Sciences Ltd.

 
 
Recommended Results 
 
Clinical Meningococcal Polysaccharide Vaccine 

  Category : Chemicals->Chemical->aspalthic products

     
Clinical Meningococcal Polysaccharide Vaccine
       

  Product Specification
 
  Model No:      0.5ml/vial
  Country  CN
  Minimum Order  5000
  Payment Term  L/C,T/T

 

    Product Detail
  <p class="MsoNormal">
The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135.
</p>
<p class="MsoNormal">
<span> [Description]<br />
The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution.<br />
Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides.<br />
Subsidiary materials: All the components of subsidiary materials approved shall be listed.<br />
Vaccine diluent: Sterile, pyrogen-free PBS.<br />
[Specifications]<br />
0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing &nbsp;200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135).</span>
</p>
<p class="MsoNormal">
<span>[Administration and dosage]<br />
(1) Reconstitute the vaccine with the accompanying PBS as the stated value. Shake and inject immediately.<br />
(2) The vaccine shall be injected s.c. at deltoid insertion area of the lateral upper arm.<br />
(3) One single human dose of 0.5 ml vaccine is required. The immunization shall be carried out before the epidemic season of epidemic cerebrospinal meningitis.<br />
[Adverse reactions]<br />
Common adverse reactions:<br />
(1) Pain, tenderness, mild or moderate erythema, swelling and infiltration at the injection site within 24 hours after vaccination, which can subside spontaneously within 2-3 days in most cases.<br />
(2) Transient fever may occur after vaccination, most of which are mild, can be relieved spontaneously within 1-2 days, and need no particular treatment. The recipients with moderate fever or the fever lasting for more than 48 hours may<br />
receive symptomatic treatment.<br />
Rare adverse reactions:<br />
(1) Severe fever: Symptomatic treatment shall be given to prevent febrile convulsion.<br />
(2) Serious erythema and, swelling at the injection site or other complications: symptomatic treatment shall be given.<br />
Extremely rare adverse reactions:<br />
(1) Allergic rash: Rash may occur with 72 hours after vaccination. Antianaphylactic treatment should be given to the recipients with rash promptly.<br />
(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination. &nbsp;Emergency treatment including injection with adrenaline shall be given promptly.<br />
(3) Allergic purpura: Antianaphylactic treatment with corticosteroid should be given to the recipients with allergic purpura. Give anti-allergic treatment with cortical steroids. If the treatment is inappropriate or delayed, purpura nephritis may be complicated.<br />
(4) Angioneurotic edema and allergic neuritis may occur occasionally.<br />
(5) Allergic exfoliative dermatitis cases have been reported occasionally.<br />
<br />
[Feature]<br />
Fill a gap in our country for the first time by developing 4-valent vaccine .<br />
Improve traditional purification technology to eliminate nucleic acid and protein.<br />
Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards.<br />
<br />
1.Group ACYW135 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br />
2.Group A+C &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />
3.prevent epidemic cerebrospinal meningitis &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</span>
</p>
<p class="MsoNormal">
<span>4.purified capsular polysaccharide antigens&nbsp;<br />
<img src="http://i.bosscdn.com/product/18/f2/13/d46381b9bd8edf65b150508726.png@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="-ACYW135" alt="-ACYW135" /><br />
<br />
</span>
</p>
<p class="MsoNormal">
<br />
</p>ccls-vaccine.com

  More Products from this Supplier
 
Medical Prevent Rabies Vaccine

Medical Prevent Rabies Vaccine
Clinical Rabies Vaccine For Human Use

Clinical Rabies Vaccine For Human Use
Prevent Hepatitis A Virus Vaccine

Prevent Hepatitis A Virus Vaccine
Trivalent Influenza vaccine (Split Virion)

Trivalent Influenza vaccine (Split Virion)
 
   


[ Back Products Catalog ]

Commerce Member:
Please log in your ID and password, we will later fill in relating info.
 
ID: Password: Remember my ID on this computer
Complete this form below to send out your enquiries.
All enquiries will be automatically sent to the company you want to develop.
Subject
Content (Don't input Company Name, E-Mail, Phone Number, Fax Number, and URL)
   

 


Company Profile:
* Company Name
*E-mail
*Country
*Contact Person
URL
*Phone
- -
Fax
- -
*Postal code
*City
*Street Address
*Business Nature
Distributor   Exporter Importer Manufacturer
Whole Sale Retailer  Reseller Retrofitter User
Others, please specify:
*Security Code
Enter the security code.


Site Map l   Privacy Policy l Company Profile l Corporate Proposal l Contact Us l Help l Advertise With Us l  World Trade Link
    .